MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal
MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.
MapLight's medicine worked really well when patients took it twice a day, but didn't work as well with just one pill a day. When a medicine doesn't fully succeed the way the company hoped, people often sell the stock first and ask questions later.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.